These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 17123900)

  • 1. Rotavirus vaccines: considerations for successful implementation in Europe.
    Van Damme P; Van der Wielen M; Ansaldi F; Desgrandchamps D; Domingo JD; Sanchez FG; Gray J; Haditsch M; Johansen K; Lorgelly P; Lorrot M; Parez N; Reschke V; Rose M
    Lancet Infect Dis; 2006 Dec; 6(12):805-12. PubMed ID: 17123900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rotavirus vaccination in central Europe.
    Mészner Z; Anca I; André F; Chlibek R; Čižman M; Grzesiowski P; Mangarov A; Pokorn M; Prymula R; Richter D; Salman N; Šimurka P; Tamm E; Tešović G; Urbancikova I; Usonis V; Zavadska D;
    J Pediatr Gastroenterol Nutr; 2013 Jun; 56(6):586-96. PubMed ID: 23708638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rotavirus vaccination in Europe: drivers and barriers.
    Parez N; Giaquinto C; Du Roure C; Martinon-Torres F; Spoulou V; Van Damme P; Vesikari T
    Lancet Infect Dis; 2014 May; 14(5):416-25. PubMed ID: 24758998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of rotavirus vaccination on hospital-acquired rotavirus gastroenteritis in children.
    Anderson EJ; Rupp A; Shulman ST; Wang D; Zheng X; Noskin GA
    Pediatrics; 2011 Feb; 127(2):e264-70. PubMed ID: 21262887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RotaTeq, a pentavalent rotavirus vaccine: efficacy and safety among infants in Europe.
    Vesikari T; Itzler R; Karvonen A; Korhonen T; Van Damme P; Behre U; Bona G; Gothefors L; Heaton PM; Dallas M; Goveia MG
    Vaccine; 2009 Dec; 28(2):345-51. PubMed ID: 19879226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Report of the Third European Expert Meeting on Rotavirus Vaccination: Progress in rotavirus universal mass vaccination in Europe.
    Huppertz H; Borte M; Schuster V; Giaquinto C; Vesikari T
    Vaccine; 2014 Jul; 32(34):4243-8. PubMed ID: 24852720
    [No Abstract]   [Full Text] [Related]  

  • 7. [Rotavirus vaccination in Europe in 2010].
    Grimprel E
    Bull Acad Natl Med; 2010 Nov; 194(8):1451-62; discussion 1462-4. PubMed ID: 22046709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing the introduction of universal rotavirus vaccination in the Netherlands.
    Zomer TP; van Duynhoven YT; Mangen MJ; van der Maas NA; Vennema H; Boot H; de Melker HE
    Vaccine; 2008 Jul; 26(29-30):3757-64. PubMed ID: 18514975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospects for routine childhood vaccination against rotavirus in India.
    Parashar U; Tate J; Arora R; Kang G
    Natl Med J India; 2012; 25(5):257-60. PubMed ID: 23448622
    [No Abstract]   [Full Text] [Related]  

  • 10. An update to "The cost-effectiveness of rotavirus vaccination: comparative analyses for five European countries and transferability in Europe".
    Jit M; Mangen MJ; Melliez H; Yazdanpanah Y; Bilcke J; Salo H; Edmunds WJ; Beutels P
    Vaccine; 2010 Nov; 28(47):7457-9. PubMed ID: 20846529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rotavirus vaccine RIX4414 (Rotarix™): a pharmacoeconomic review of its use in the prevention of rotavirus gastroenteritis in developing countries.
    Plosker GL
    Pharmacoeconomics; 2011 Nov; 29(11):989-1009. PubMed ID: 21988293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and immunogenicity of live-attenuated human rotavirus vaccine in breast-fed and formula-fed European infants.
    Vesikari T; Prymula R; Schuster V; Tejedor JC; Cohen R; Bouckenooghe A; Damaso S; Han HH
    Pediatr Infect Dis J; 2012 May; 31(5):509-13. PubMed ID: 22228235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Herd immunity after two years of the universal mass vaccination program against rotavirus gastroenteritis in Austria.
    Paulke-Korinek M; Kundi M; Rendi-Wagner P; de Martin A; Eder G; Schmidle-Loss B; Vecsei A; Kollaritsch H
    Vaccine; 2011 Mar; 29(15):2791-6. PubMed ID: 21320539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cost of vaccination and cost of sick leave are determinants of cost-effectiveness vaccination against rotavirus].
    Gyrd-Hansen D; Olsen KR
    Ugeskr Laeger; 2012 Feb; 174(8):480-3. PubMed ID: 22348668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rotavirus in Asia: the value of surveillance for informing decisions about the introduction of new vaccines.
    Bresee JS; Hummelman E; Nelson EA; Glass RI
    J Infect Dis; 2005 Sep; 192 Suppl 1():S1-5. PubMed ID: 16088790
    [No Abstract]   [Full Text] [Related]  

  • 16. Ecological assessment of the direct and indirect effects of routine rotavirus vaccination in Merseyside, UK using data from multiple health systems: a study protocol.
    Hungerford D; Vivancos R; French N; Iturriza-Gomara M; Cunliffe N
    BMJ Open; 2014 Nov; 4(11):e006161. PubMed ID: 25424995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of nonspecific protection against all-cause nonrotavirus gastroenteritis by vaccination with orally administered rotavirus vaccine.
    Grant L; Watt J; Moulton L; Weatherholtz R; Reid R; Santosham M; O'Brien K
    J Pediatr Gastroenterol Nutr; 2013 Jun; 56(6):635-40. PubMed ID: 23343932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rotavirus vaccination in Europe: the time has finally arrived.
    Parashar UD; Glass RI
    J Pediatr Gastroenterol Nutr; 2008 May; 46 Suppl 2():S21-3. PubMed ID: 18460968
    [No Abstract]   [Full Text] [Related]  

  • 19. Rotavirus vaccines. WHO position paper – January 2013.
    Wkly Epidemiol Rec; 2013 Feb; 88(5):49-64. PubMed ID: 23424730
    [No Abstract]   [Full Text] [Related]  

  • 20. Effectiveness and impact of rotavirus vaccines in Europe, 2006-2014.
    Karafillakis E; Hassounah S; Atchison C
    Vaccine; 2015 Apr; 33(18):2097-107. PubMed ID: 25795258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.